Researchers at Washington University School of Medicine in St. Louis found that gene therapy in mice helped build strength and significant muscle mass quickly, while reducing the severity of osteoarthritis. The gene therapy also prevented obesity, even when the mice were fed a high-fat diet.
Exercise and physical therapy often are recommended to help people who have arthritis. Both can strengthen muscle — a benefit that also can reduce joint pain. But building muscle mass and strength can take many months and be difficult in the face of joint pain from osteoarthritis, particularly for older people who are overweight.
A new study in mice at Washington University School of Medicine in St. Louis, however, suggests gene therapy one day may help those patients.
The research shows that gene therapy helped build significant muscle mass quickly and reduced the severity of osteoarthritis in the mice, even though they didn’t exercise more. The therapy also staved off obesity, even when the mice ate an extremely high-fat diet.
The study is published online May 8 in the journal Science Advances.
“Obesity is the most common risk factor for osteoarthritis,” said senior investigator Farshid Guilak, PhD, the Mildred B. Simon Research Professor of Orthopaedic Surgery and director of research at Shriners Hospitals for Children — St. Louis. “Being overweight can hinder a person’s ability to exercise and benefit fully from physical therapy. We’ve identified here a way to use gene therapy to build muscle quickly. It had a profound effect in the mice and kept their weight in check, suggesting a similar approach may be effective against arthritis, particularly in cases of morbid obesity.”
With the paper’s first author, Ruhang Tang, PhD, a senior scientist in Guilak’s laboratory, Guilak and his research team gave 8-week-old mice a single injection each of a virus carrying a gene called follistatin. The gene works to block the activity of a protein in muscle that keeps muscle growth in check. This enabled the mice to gain significant muscle mass without exercising more than usual.
Even without additional exercise, and while continuing to eat a high-fat diet, the muscle mass of these “super mice” more than doubled, and their strength nearly doubled, too. The mice also had less cartilage damage related to osteoarthritis, lower numbers of inflammatory cells and proteins in their joints, fewer metabolic problems, and healthier hearts and blood vessels than littermates that did not receive the gene therapy. The mice also were significantly less sensitive to pain.
One worry was that some of the muscle growth prompted by the gene therapy might turn out to be harmful. The heart, for example, is a muscle, and a condition called cardiac hypertrophy, in which the heart’s walls thicken, is not a good thing. But in these mice, heart function actually improved, as did cardiovascular health in general.
Longer-term studies will be needed to determine the safety of this type of gene therapy. But, if safe, the strategy could be particularly beneficial for patients with conditions such as muscular dystrophy that make it difficult to build new muscle.
In the meantime, Guilak, who also co-directs the Washington University Center for Regenerative Medicine and is a professor of biomedical engineering and of developmental biology, said more traditional methods of muscle strengthening, such as lifting weights or physical therapy, remain the first line of treatment for patients with osteoarthritis.
“Something like this could take years to develop, but we’re excited about its prospects for reducing joint damage related to osteoarthritis, as well as possibly being useful in extreme cases of obesity,” he said.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- New method using light-activated liposomes is safer, more direct to deliver CRISPR gene therapyon November 12, 2020 at 4:19 pm
Light-activated liposomes could help to deliver CRISPR gene therapy - and the method could prove safer and more direct than current methods.
- Medical Moment: Groundbreaking gene replacement therapyon November 12, 2020 at 2:37 pm
SOUTH BEND, Ind. (WNDU) - This little cowboy was saved by a groundbreaking new therapy. His live-saving drug was approved just in time. Details in today’s Medical Moment. Gene replacement therapy: ...
- UCB boosts gene therapy footprint with two new dealson November 12, 2020 at 11:27 am
Aimed at beefing up its activities in gene therapies, UCB SA (OTCPK:UCBJF) has acquired Leuven, Belgium-based Handl Therapeutics BV, a developer of AAV gene therapies for neurodegenerative disorders, ...
- 'This is just the beginning': Cell and gene therapy pioneers June and Marrazzo on industry’s past, future (Video)on November 12, 2020 at 10:06 am
"This is just the beginning." Here's what two cell and gene therapy pioneers – Dr. Carl June of Penn and Jeff Marrazzo of Spark Therapeutics – had to say about the past, present and future of the ...
- Philadelphia’s 'hungry' cell and gene therapy companies seek more lab space, capital to fuel growth (Video)on November 12, 2020 at 8:56 am
Philadelphia has the potential to generate thousands of jobs and create dozens of new companies in the cell and gene therapy industry, but local CEOs say the region's lack of lab space, local capital ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Gene therapy for osteoarthritis and obesity
- Cell Therapy and Gene Therapy Markets, 2019-2020 & Forecast to 2025 and 2030 - ResearchAndMarkets.comon November 11, 2020 at 2:50 am
The "Cell Therapy and Gene Therapy Markets" report has been added to ResearchAndMarkets.com's offering. This is an exciting and interesting time in the cell and gene therapy industry. The science is ...
- Musculoskeletal System Disorders Market :Global Industry Analysis By Development, Size, Share And Demand Forecast From 2020 To 2025on November 5, 2020 at 11:35 pm
Market Forecast The Global Musculoskeletal System Disorders Market is expected to cross USD 5.73 Billion by 2025 at a ...
- Flexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business Highlights - MarketWatchon November 4, 2020 at 8:01 am
Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended September 30, 2020. "Throughout the third quarter, we saw strong ...
- Why Flexion Therapeutics (FLXN) Stock is a Compelling Investment Caseon November 2, 2020 at 8:55 am
Miller Value Partners recently released its Q3 2020 Investor Letter, a copy of which you can download here. The Opportunity Equity Fund posted a return of 13.01% for the quarter (net of fees), ...
- Novartis alums Jimenez, Fishman unveil their next act: Aditum Bioon November 2, 2020 at 3:00 am
After 11 years in the biopharma biz and eight at the Swiss drugmaker’s helm, he was ready to build something from scratch. Now, he’s unveiling that something: Aditum Bio, a biotech investment firm he ...